Vanguard Capital Management
KRYS icon

Vanguard Capital Management’s Krystal Biotech KRYS Stock Holding History

Vanguard Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$461M Buy
1,240,567
+75,243
+6% +$22.5M 0.01% 737
2026
Q1 		$301M Buy
+1,165,324
New +$310M 0.01% 847

Other funds holding KRYS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Vanguard Capital Management's KRYS Position: Q2 2026 in Review

Vanguard Capital Management increased its Krystal Biotech (KRYS) stake by 6.5% in Q2 2026, buying an estimated $22.5M and bringing the position to 1,240,567 shares worth $461M. The position accounts for 0.01% of the portfolio, ranked #737.

Vanguard Capital Management first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 398 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Vanguard Capital Management held 1,240,567 shares of Krystal Biotech worth $461M as of Q2 2026.
  • Vanguard Capital Management bought 75,243 Krystal Biotech shares in Q2 2026, an estimated $22.5M.
  • Krystal Biotech made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #737 holding.
  • Vanguard Capital Management first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 398 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.